ReviewBlood2013
Smoldering multiple myeloma requiring treatment: time for a new definition?
Review in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study.Blood cancer journal · 2025Article
- Can we identify individuals at risk to develop multiple myeloma? A machine learning-based predictive model.British journal of haematology · 2025Article
- Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible.Haematologica · 2024Review
- [Imaging for Multiple Myeloma according to the Recent International Myeloma Working Group Guidelines: Analysis of Image Acquisition Techniques and Response Evaluation in Whole-Body MRI according to MY-RADS].Journal of the Korean Society of Radiology · 2023Review
- Factors Explaining the Coincidence of Smoldering Multiple Myeloma and Primary Biliary Cholangitis: A Case Report.Cureus · 2022Article
- Review
- Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.Current oncology (Toronto, Ont.) · 2021Article
- In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells.Cancer & metabolism · 2020Article
- Review
- Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.JAMA oncology · 2020Review
- A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.Blood advances · 2019Article
- Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.JCI insight · 2018Article
- Shall we treat smoldering multiple myeloma in the near future?Hematology. American Society of Hematology. Education Program · 2017Review
- Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Singapore medical journal · 2017Article
- Prevalence, incidence and survival of smoldering multiple myeloma in the United States.Blood cancer journal · 2016Article
- Recent advances in multiple myeloma: a Korean perspective.The Korean journal of internal medicine · 2016Review
- The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.The oncologist · 2016Review
- Smoldering multiple myeloma.Blood · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myeloma-related events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.